912P - Prognosis of diffuse large B-cell lymphoma: 16 years of experience

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Lymphomas
Presenter Ece Esin
Citation Annals of Oncology (2016) 27 (6): 313-327. 10.1093/annonc/mdw375
Authors E. Esin1, A. Saglam2, M. Hayran3, A. Uner2
  • 1Medical Oncology Dep., Hacettepe University Faculty of Medicine, 06100 - Ankara/TR
  • 2Pathology Dep., Hacettepe University Faculty of Medicine, 06100 - Ankara/TR
  • 3Preventive Oncology, Hacettepe University Faculty of Medicine, 06100 - Ankara/TR



Diffuse large B-cell lymphoma (DLBCL) accounts for the majority of cases of non-Hodgkin's lymphoma in our country. However, little is known about its clinical and demographic data and prognosis. The aim of this study is to summarize the demographics and to investigate the prognosis of DLBCL patients from a tertiary reference hospital in Turkey over the past 16 years.


This study was designed as a retrospective cohort study. Patient who were diagnosed and/or treated at the University of Hacettepe between 1/2000 and 11/2015 were included. A chart review was conducted to access the clinical and demographic data. Main outcome measures [overall survival (OS), survival after progression (time from relapse to second progression or death, SAP)] were calculated.


A total of 939 cases were included. Mean age of patients was 54 ± 17; 54% of the patients were male and 43.8% were female. Ann Arbor stages at presentation were as follows: stage-1 in 15.8% of patients, stage-2 in 23.4%, stage-3 in 21.1% and 39.7% as stage-4. It is of note that extranodal involvement was prominent (64.6%). The most prevelant extranodal sites were gastrointestinal system (17.3%), central nervous system (4.4%), bone (4.4%), skin (2.4%) and liver (2%). Mean overall survival was 94 ± 12.3 months. At 5 years, 93.2% of patients were alive and at 10 years 85.2% of patients were alive. There was a statistically significant survival difference between stage III and IV patients (p 


Extranodal presentation is more common in DLBCLs in Turkey and clinical parameters such as stage, EN status and BM involvement are the main prognostic factors.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.